Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer By Ogkologos - August 12, 2025 771 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the IoN study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Grants Accelerated Approval to Tafasitamab-cxix for DLBCL August 7, 2020 EMA Recommends Extension of Therapeutic Indications for Selpercatinib August 25, 2022 Can I Have a Nonviolent Relationship with Cancer? (Part 1) November 15, 2021 The Combination of Nivolumab and Cabozantinib Provides a New First-Line Treatment... September 19, 2020 Load more HOT NEWS Triple Blockade Demonstrates High Response Rates in Metastatic Melanoma FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with... FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine... Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer
